We are analyzing https://link.springer.com/article/10.1007/s40265-018-0937-z.

Title:
Empagliflozin: A Review in Type 2 Diabetes | Drugs
Description:
Empagliflozin (Jardiance®), a potent, highly selective, sodium glucose cotransporter-2 (SGLT2) inhibitor, is an effective and generally well tolerated antihyperglycaemic agent approved for the treatment of adults with type 2 diabetes (T2D) in the EU, USA and Japan, among other parts of the world. As with other members of its class, empagliflozin offers the convenience of once-daily oral administration and carries a low inherent risk of hypoglycaemia as a result of its insulin-independent mechanism of action, enabling it to be used as monotherapy and as a component of combination therapy with other antidiabetic agents with complementary modes of action to improve glycaemic control in patients with T2D. Beyond lowering glucose, empagliflozin exerts a favourable effect on a number of nonglycaemic outcomes, including modest reductions in bodyweight and blood pressure. As an adjunct to standard care, it demonstrated cardioprotective and renoprotective properties largely independent of glycaemic control in patients with T2D and established cardiovascular disease (CVD) in a mandated cardiovascular (CV) outcomes trial (EMPA-REG OUTCOME). Empagliflozin is generally well tolerated as monotherapy or as add-on therapy and, unlike canagliflozin (the only other SGLT2 inhibitor that has so far shown CV and renal benefits), it has not been associated with an increased risk of amputation or bone fractures. In conclusion, empagliflozin is a valuable treatment option for the management of T2D. Given its demonstrable cardioprotective benefits, the drug is worthy of preferential consideration in patients at high CV risk who require an (additional) antidiabetic medication in order to attain their glycaemic goal.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

diabetes, pubmed, article, google, scholar, empagliflozin, type, cas, patients, cardiovascular, care, trial, central, empareg, outcome, sglt, treatment, disease, mellitus, suppl, risk, safety, abstract, outcomes, inhibitors, placebocontrolled, cotransporter, randomized, review, addon, clinical, heart, inzucchi, metab, doubleblind, drugs, obes, trials, metformin, june, therapy, effect, management, phase, kidney, med, zinman, university, content, analysis,

Topics {✒️}

month download article/chapter /prescribing%20information/pis/jardiance/jardiance 25 mg film-coated tablets placebo-controlled clinical trials empa-reg outcome trial empa-reg outcome [abstract empa-reg outcome study randomized placebo-controlled trials sodium-glucose cotransporter-2 inhibitors empa-reg outcome randomised american diabetes association full article pdf article drugs aims privacy choices/manage cookies european economic area related subjects clinical practice placebo-controlled trial iii clinical trials composite outcomes related empa-reg outcome empa-reg outcome™ european association cefalu wt sodium glucose cotransporter-2 established cardiovascular disease chronic kidney disease drug-naive patients randomized controlled trials empa-reg study parallel-group trial lower-limb amputations beta-cell function phase iii trials peripheral artery disease low inherent risk sglt-2 inhibitors versus euglycemic diabetic ketoacidosis advanced kidney disease chronic heart failure american association diabetes obes metab including modest reductions patient-centered approach boehringer ingelheim pharmaceuticals ampudia-blasco fj translational viewpoint explaining nat rev endocrinol article content ziekenhuis oost-limburg

Questions {❓}

Cardiovascular outcomes trials in type 2 diabetes: where do we go from here?
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Does lower limb amputation concern all SGLT2 inhibitors?
How does empagliflozin reduce cardiovascular mortality?
The EMPA-REG study: what has it told us?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Empagliflozin: A Review in Type 2 Diabetes
         description:Empagliflozin (Jardiance®), a potent, highly selective, sodium glucose cotransporter-2 (SGLT2) inhibitor, is an effective and generally well tolerated antihyperglycaemic agent approved for the treatment of adults with type 2 diabetes (T2D) in the EU, USA and Japan, among other parts of the world. As with other members of its class, empagliflozin offers the convenience of once-daily oral administration and carries a low inherent risk of hypoglycaemia as a result of its insulin-independent mechanism of action, enabling it to be used as monotherapy and as a component of combination therapy with other antidiabetic agents with complementary modes of action to improve glycaemic control in patients with T2D. Beyond lowering glucose, empagliflozin exerts a favourable effect on a number of nonglycaemic outcomes, including modest reductions in bodyweight and blood pressure. As an adjunct to standard care, it demonstrated cardioprotective and renoprotective properties largely independent of glycaemic control in patients with T2D and established cardiovascular disease (CVD) in a mandated cardiovascular (CV) outcomes trial (EMPA-REG OUTCOME). Empagliflozin is generally well tolerated as monotherapy or as add-on therapy and, unlike canagliflozin (the only other SGLT2 inhibitor that has so far shown CV and renal benefits), it has not been associated with an increased risk of amputation or bone fractures. In conclusion, empagliflozin is a valuable treatment option for the management of T2D. Given its demonstrable cardioprotective benefits, the drug is worthy of preferential consideration in patients at high CV risk who require an (additional) antidiabetic medication in order to attain their glycaemic goal.
         datePublished:2018-06-27T00:00:00Z
         dateModified:2018-06-27T00:00:00Z
         pageStart:1037
         pageEnd:1048
         sameAs:https://doi.org/10.1007/s40265-018-0937-z
         keywords:
            Pharmacotherapy
            Pharmacology/Toxicology
            Internal Medicine
         image:
         isPartOf:
            name:Drugs
            issn:
               1179-1950
               0012-6667
            volumeNumber:78
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:James E. Frampton
               affiliation:
                     name:Springer
                     address:
                        name:Springer, Auckland, New Zealand
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Empagliflozin: A Review in Type 2 Diabetes
      description:Empagliflozin (Jardiance®), a potent, highly selective, sodium glucose cotransporter-2 (SGLT2) inhibitor, is an effective and generally well tolerated antihyperglycaemic agent approved for the treatment of adults with type 2 diabetes (T2D) in the EU, USA and Japan, among other parts of the world. As with other members of its class, empagliflozin offers the convenience of once-daily oral administration and carries a low inherent risk of hypoglycaemia as a result of its insulin-independent mechanism of action, enabling it to be used as monotherapy and as a component of combination therapy with other antidiabetic agents with complementary modes of action to improve glycaemic control in patients with T2D. Beyond lowering glucose, empagliflozin exerts a favourable effect on a number of nonglycaemic outcomes, including modest reductions in bodyweight and blood pressure. As an adjunct to standard care, it demonstrated cardioprotective and renoprotective properties largely independent of glycaemic control in patients with T2D and established cardiovascular disease (CVD) in a mandated cardiovascular (CV) outcomes trial (EMPA-REG OUTCOME). Empagliflozin is generally well tolerated as monotherapy or as add-on therapy and, unlike canagliflozin (the only other SGLT2 inhibitor that has so far shown CV and renal benefits), it has not been associated with an increased risk of amputation or bone fractures. In conclusion, empagliflozin is a valuable treatment option for the management of T2D. Given its demonstrable cardioprotective benefits, the drug is worthy of preferential consideration in patients at high CV risk who require an (additional) antidiabetic medication in order to attain their glycaemic goal.
      datePublished:2018-06-27T00:00:00Z
      dateModified:2018-06-27T00:00:00Z
      pageStart:1037
      pageEnd:1048
      sameAs:https://doi.org/10.1007/s40265-018-0937-z
      keywords:
         Pharmacotherapy
         Pharmacology/Toxicology
         Internal Medicine
      image:
      isPartOf:
         name:Drugs
         issn:
            1179-1950
            0012-6667
         volumeNumber:78
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:James E. Frampton
            affiliation:
                  name:Springer
                  address:
                     name:Springer, Auckland, New Zealand
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Drugs
      issn:
         1179-1950
         0012-6667
      volumeNumber:78
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Springer
      address:
         name:Springer, Auckland, New Zealand
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:James E. Frampton
      affiliation:
            name:Springer
            address:
               name:Springer, Auckland, New Zealand
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Springer, Auckland, New Zealand
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(240)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.22s.

LINK . SPRINGER . COM {}